echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Prof. Lugui Qiu: Zebutinib was recommended as a priority in Class I of the 2023 V1 NCCN Guidelines

    Prof. Lugui Qiu: Zebutinib was recommended as a priority in Class I of the 2023 V1 NCCN Guidelines

    • Last Update: 2022-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    NCCN Guidelines Update and Interpretation Expert Introduction


    First- and second-line treatment of CLL/SLL preferred status

    In recent years, the treatment of CLL/SLL has undergone a historic change



    The 2022 NCCN CLL/SLL Guideline V2[2] has included zebutinib in the preferred recommended treatment status for the CLL/SLL first- and second-line lines



    Zebutinib brings longer survival to CLL/SLL

    In fact, for the treatment of CLL/SLL patients, the first-generation BTK inhibitor ibratinib ushered in the era of



    A large global phase III ALPINE study comparing the generation of BTK inhibitor ibretinib in the global study[4], zebutinib vs.



    The 2023 LCCN CLL/SLL guideline V1 transfers the generation of BTK inhibitor ibratinib from the original priority recommendation to other recommended protocols in all first- and second-tier populations



    In the ALPINE head-to-head comparison study with ibretinib, the incidence of atrial flutter/atrial fibrillation in the zebutinib group was 2.


    Click "Read the original article" to see more information

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.